Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 1, 2015, Pages 28-34

  Müller, Rüdiger B ^a   von Kempis, Johannes ^a   Haile, Sarah R ^b   Schiff, Michael H ^c  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Methotrexate; Rheumatoid arthritis; Subcutaneous

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ALLERGIC REACTION; ANEURYSM RUPTURE; ARTHRITIS; ARTICLE; BIOLOGICAL THERAPY; CARPAL TUNNEL SYNDROME; CATARACT; CHOLANGITIS; COUGHING; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPERTRANSAMINASEMIA; INCONTINENCE; INFECTION; INTERSTITIAL LUNG DISEASE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LONGITUDINAL STUDY; LOW BACK PAIN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PARKINSONISM; PNEUMONIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCIATICA; SOFT TISSUE INFECTION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UROSEPSIS; VERTEBRAL CANAL STENOSIS; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937727375     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.02.009     Document Type: Article

References (40)

1. Aletaha D., Smolen J.S. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002, 29:1631-1638.
2. Bannwarth B., Labat L., Moride Y., Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994, 47:25-50.
3. Yazici Y., Sokka T., Kautiainen H., Swearingen C., Kulman I., Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005, 64:207-211.
4. Wluka A., Buchbinder R., Mylvaganam A., Hall S., Harkness A., Lewis D., et al. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol 2000, 27:1864-1871.
5. Kremer J.M., Phelps C.T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992, 35:138-145.
6. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
7. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
8. Kavanaugh A., Fleischmann R.M., Emery P., Kupper H., Redden L., Guerette B., et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013, 72:64-71.
9. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
10. Tak P.P., Rigby W.F., Rubbert-Roth A., Peterfy C.G., van Vollenhoven R.F., Stohl W., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
11. Westhovens R., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009, 68:1870-1877.
12. Heimans L., Wevers-de Boer K.V., Visser K., Goekoop R.J., van Oosterhout M., Harbers J.B., et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 2014, 73:1356-1361.
13. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
14. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
15. Visser K., van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009, 68:1094-1099.
16. Hamilton R.A., Kremer J.M. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997, 36:86-90.
17. Hoekstra M., Haagsma C., Neef C., et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004, 31:645-648.
18. Wegrzyn J., Adeleine P., Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004, 63:1232-1234.
19. Schiff M., Jaffe J., Freundlich B. Head-to-head, randomized, crossover study of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≤15mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014, 73:1549-1551.
20. Tian H., Cronstein B.N. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007, 65:168-173.
21. Rutkowska-Sak L., Rell-Bakalarska M., Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 2009, 47:207-211.
22. Bykerk V.P., Akhavan P., Hazlewood G.S., Schieir O., Dooley A., Haraoui B., et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012, 39:1559-1582.
23. Hoffmeister R.T. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983, 75:69-73.
24. National Guideline Clearinghouse. Update of the clinical practice guideline for the management of rheumatoid arthritis in Spain. Secondary Update of the clinical practice guideline for the management of rheumatoid arthritis in Spain. 〈〉. http://www.guideline.gov/content.aspx?id=36829.
25. Kruger K., Wollenhaupt J., Albrecht K., Alten R., Backhaus M., Baerwald C., et al. German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. Z Rheumatol 2012, 71:592-603.
26. Chakravarty K., McDonald H., Pullar T., Taggart A., Chalmers R., Oliver S., et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008, 47:924-925.
27. Mainman H., McClaren E., Heycock C., Saravanan V., Hamilton J., Kelly C. When should we use parenteral methotrexate?. Clin Rheumatol 2010, 29:1093-1098.
28. Braun J., Kastner P., Flaxenberg P., et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008, 58:73-81.
29. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
30. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
31. Wickham H. ggplot2: Elegant Graphics for Data Analysis 2009.
32. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest: tests for random and fixed effects for linear mixed effect models (lmer objects of lme4 package). R package version 1.0-2. 〈〉 2012. http://www.cran.r-project.org/package=lmerTest.
33. TEAM RC. R Foundation for Statistical Computing. Secondary R: a language and environment for statistical computing. 〈〉 2013. http://www.R-project.org.
34. Ng B., Chu A. Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. Clin Rheumatol 2014, 33:21-30.
35. Moreland L.W., O'Dell J.R., Paulus H.E., Curtis J.R., Bathon J.M., Clair E.W., et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012, 64:2824-2835.
36. van Vollenhoven R.F., Ernestam S., Geborek P., Petersson I.F., Cöster L., Waltbrand E., et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009, 374:459-466.
37. Verstappen S.M., Jacobs J.W., van der Veen M.J., Heurkens A.H., Schenk Y., ter Borg E.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449.
38. Bakker M.F., Jacobs J.W., Welsing P.M., van der Werf J.H., Linn-Rasker S.P., van der Veen M.J., et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010, 69:1849-1852.
39. Pincus T., Furer V., Sokka T. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol 2010, 28(5 Suppl 61):S68-S79.
40. van der Woude D., Syversen S.W., van der Voort E.I., Verpoort K.N., Goll G.L., van der Linden M.P., et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2010, 69:1110-1116.